Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LCTX with free AI briefings, catalyst countdowns, and dilution alerts.

LCTX · Lineage Cell Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$49.9M Cash on Hand
23.3mo Cash Runway
16% Short Interest
$5.5 Analyst Target (6)
Follow LCTX by email Get an email when LCTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LCTX, unsubscribe in one click. Privacy

📣 What LCTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AST-OPC1 Cervical Spinal Cord Injury Phase 1/2 · NCT02302157 Completed
GRNOPC1 Spinal Cord Injury Phase 1 · NCT01217008 Completed
OPC1 Spinal Cord Injury Cervical Phase 1 · NCT06841770 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LCTX holds $49.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.4M/quarter from operations, an estimated runway of 23.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LCTX files for a raise →

👥 Who Owns LCTX

Insiders 19.9% Institutions (178 holders) 48.2% Public and other holders 31.9%
HolderTypeShares% of sharesAs of
NEAL C. BRADSHER Institution (13G, 5%+) 57,848,357 22.87% 2025-11-12
BROADWOOD PARTNERS, L.P.
Director, 10% owner · +7.89M options
Insider 49,648,620 19.63% 2025-01-27
BlackRock, Inc. Institution (13G, 5%+) 13,185,489 5.21% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 8,775,663 3.47% 2026-09-30
Defender Capital, LLC Institution (13F) 6,648,899 2.63% 2026-09-30
Geode Capital Management, LLC Institution (13F) 5,339,354 2.11% 2026-09-30
Raffles Associates Lp Institution (13F) 5,197,788 2.06% 2026-09-30
Fifth Third Bancorp Institution (13F) 4,900,000 1.94% 2026-09-30
State Street Corporation Institution (13F) 2,925,731 1.16% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 1,715,125 0.68% 2026-09-30
Michael H. Mulroy
Director · +275,000 options
Insider 298,555 0.12% 2024-11-22
Brian M Culley
President and CEO, Director · +7.45M options
Insider 255,516 0.10% 2026-03-12

Share count 252,907,464 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-07-01
filed 2026-07-02
Jayasuriya Anula
Option award (A) 125,000 – –
2026-07-01
filed 2026-07-02
Russell Angus C.
Option award (A) 125,000 – –
2026-07-01
filed 2026-07-02
Mulroy Michael H.
Option award (A) 125,000 – –
2026-07-01
filed 2026-07-02
ANDREWS DEBORAH J
Option award (A) 125,000 – –
2026-07-01
filed 2026-07-02
Bradsher Neal C
Option award (A) 125,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full LCTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LCTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.